Cipla Shares Fall 3% Despite Eli Lilly Weight Loss Drug Deal
Cipla's stock faces unexpected pressure despite securing rights to manufacture and distribute Eli Lilly's revolutionary weight loss drug Mounjaro in India. Discover why investors remain cautious.